13
Jul
2009
Posted in I - Series C, Q - 2Q09, R - WEST, X - GI, X - Hepatology, XX - CA
Hyperion Therapeutics (San Francisco, CA) a clinical-stage specialty pharmaceutical company focused on gastroenterology and hepatology, closed a $60M Series C financing. Participants include Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates, Sofinnova Ventures, and WRF Capital.
13
Jul
2009
Posted in I - Series A, Q - 2Q09, R - WEST, X - Antiviral, X - Therapeutic Platform, XX - CA
Alios BioPharma (San Francisco, CA) a preclinical-stage small molecule and protein therapeutics company focused on viral disease via innate immune modulation, closed a $8M Series A financing bring the total round to $32M. Participants include SR One, Novo Ventures, Novartis Venture Fund and Roche Venture Fund.
13
Jul
2009
Posted in I - Series D, Q - 2Q09, R - MID WEST, X - Device (Spine), XX - MN
Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $10.2M Series D financing. Participants include Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
13
Jul
2009
Posted in I - Series B, Q - 2Q09, R - INTERNATIONAL, X - Device (Cardiology), X - Device (Stent)
Stentys (France) a clinical-stage medical device company focused on stents designed for treatment of acute myocardial infarction and coronary artery bifurcations, closed a $4.2M Series B financing bringing the round total to $22.2M. Participants include Crédit Agricole Private Equity, Sofinnova Partners and Scottish Equity Partners.
07
Jul
2009
Posted in I - Series C, Q - 2Q09, R - NORTH EAST, X - Device (GYN), XX - MA
Interlace Medical (Framingham, MA) a near commercial-stage gynecological medical device company focused MIS removal of intrauterine fibroids and polyps, closed a $20M Series C financing. Participants include Baird Venture Partners, HLM Venture Partners, Hambrecht & Quist Capital Management, Aperture Venture Partners, New Leaf Venture Partners and Spray Venture Partners.
07
Jul
2009
07
Jul
2009
07
Jul
2009
07
Jul
2009
07
Jul
2009
Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Immunology, X - Inflammation, X - Metabolism, X - Oncology, XX - MA
Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.
07
Jul
2009
07
Jul
2009
06
Jul
2009